Basophils and allergic inflammation - 27/09/13

Abstract |
Basophils were discovered by Paul Ehrlich in 1879 and represent the least abundant granulocyte population in mammals. The relative rarity of basophils and their phenotypic similarities with mast cells resulted in this cell lineage being historically overlooked, both clinically and experimentally. However, recent studies in human subjects and murine systems have shown that basophils perform nonredundant effector functions and significantly contribute to the development and progression of TH2 cytokine–mediated inflammation. Although the potential functions of murine and human basophils have provoked some controversy, recent genetic approaches indicate that basophils can migrate into lymphoid tissues and, in some circumstances, cooperate with other immune cells to promote optimal TH2 cytokine responses in vivo. This article provides a brief historical perspective on basophil-related research and discusses recent studies that have identified previously unappreciated molecules and pathways that regulate basophil development, activation, and function in the context of allergic inflammation. Furthermore, we highlight the unique effector functions of basophils and discuss their contributions to the development and pathogenesis of allergic inflammation in human disease. Finally, we discuss the therapeutic potential of targeting basophils in preventing or alleviating the development and progression of allergic inflammation.
Le texte complet de cet article est disponible en PDF.Key words : Basophil, allergy, TH2 cytokine, thymic stromal lymphopoietin, allergic rhinitis, asthma, atopic dermatitis, urticaria, food allergy, eosinophilic esophagitis, IgE
Abbreviations used : AD, APC, AR, BaP, BAT, CIU, EMH, EoE, FDA, GMP, HDM, HSC, LTC4, MCP, MyD88, TSLP
Plan
| Series editors: Joshua A. Boyce, MD, Fred Finkelman, MD, and William T. Shearer, MD, PhD |
|
| Research in the Artis laboratory is supported by the National Institutes of Health (AI061570, AI087990, AI074878, AI095776, AI102942, AI095466, AI095608, and AI097333 to D.A.), Advanced Research Fellowships (KL2-RR024132 to B.S.K. and F32-AI085828 to M.C.S.), and the Burroughs Wellcome Fund Investigator in Pathogenesis of Infectious Disease Award (to D.A.). |
|
| Disclosure of potential conflict of interest: M. C. Siracusa, B. S. Kim, and D. Artis have received grants from the National Institutes of Health (NIH) and have received payment for preparation of this manuscript from the Journal of Allergy and Clinical Immunology. J. M. Spergel has received a grant from the Department of Defense and has received a consulting fee/honorarium from DBV Tech; has consultant arrangements with Danone; has provided expert testimony in a malpractice case on immunotherapy; has received grants from Food Allergy Research Education and the NIH; has received payment for lectures and development of educational presentations from MEI; and has stock/stock options in DBV. |
|
| Terms in boldface and italics are defined in the glossary on page 790. |
Vol 132 - N° 4
P. 789-801 - octobre 2013 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
